← Back to all trials
Enrolling By Invitation
NCT03123458
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
Conditions: Immune Related Disorder, Tissue Damage
Sex: All
Ages: 1 Year – 80 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 100
Sponsor: Shenzhen Geno-Immune Medical Institute
Location: Shenzhen Geno-immune Medical Institute Shenzhen Guangdong
Summary
The primary objectives are to evaluate the safety and efficacy of infusion of the third party fully-characterized clonally derived fetal MSCs (cfMSCs) for the control of severe symptoms associated with acute and chronic immune-related disorders and tissue damage.
Eligibility Criteria
Inclusion Criteria:
1. Informed consent.
2. No available alternative treatment that can reduce the symptoms
3. Patients are required to meet the following inclusion criteria:
* Any patient that has clinically documented abnormal immune or age-related disorders including acute and chronic GVHD. Patients may receive best available treatment for the control of disease symptoms.
* Patients with symptoms associated with genetic defects or infectious diseases are not eligible.
Exclusion Criteria:
1. Inability to give informed consent.
2. Patients with ongoing infection or history of cancer.
3. Patients with poor clinical conditions with the life expectancy of less than 14 days.
4. Pregnancy.
Source: ClinicalTrials.gov (NCT03123458). StuddyBuddy aggregates publicly available trial information.
